General Information
Revision date
2014-08-15
Product name
Raloxifene Hydrochloride Tablets, USP 60 mg
Product Synonyms
Raloxifene Hydrochloride Tablets
Chemical name
Methanone, [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl]-[4- [2-(1-piperidinyl) ethoxy] phenyl]-, hydrochloride
CAS No.
82640-04-8
1.2.1 Relevant identified uses
and weight C28H27NO4.S.HCl and Wt 510.04
Emergency telephone
InvaGen Pharmaceuticals Inc
Icons in SDS
Company Information
company name
InvaGen Pharmaceuticals Inc
Section 2
SECTION 2: Hazards identification
OSHA Not considered hazardous when handled under normal conditions. EMERGENCY OVERVIEW Caution Statement: Intact Raloxifene Hydrochloride Tablets, USP are not considered to be a health hazard. Effects of exposure to contents may cause skin irritation, Highly Potent and Reproductive Hazard.
Principle Routes of Exposure
Oral Effects of Overexposure: Tablets are intended for human consumption under guidance of a physician. Intact tablets are not considered hazardous under normal handling procedures.
Medical Conditions Generally Aggravated by Exposure
Hypersensitivity to material; active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis; heart problems; neoplasms; impaired liver or kidney function; and undiagnosed uterine bleeding. Carcinogenicity: Raloxifene hydrochloride - Not listed by IARC, NTP and OSHA.
